Business Context and Reporting Period
Compass Therapeutics, Inc. filed this Form 8-K on December 12, 2020, to report the entry into a material definitive agreement. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or debt levels. The primary financial obligation disclosed is a new lease agreement with the following terms:
- Monthly Base Rent: $106,709, commencing January 1, 2021.
- Rent Escalation: 2.5% annual increase.
- Additional Costs: Company responsible for insurance, pro rata operating expenses, and applicable taxes.
- Lease Term: Through May 2025.
Material Changes
The Company entered into a Sublease with Roche Diagnostics Operations for a 19,112 square foot facility at 80 Guest Street in Brighton, Massachusetts. In January 2021, the Company will relocate all functions, including its corporate headquarters, from Cambridge, Massachusetts, to this new facility.
Outlook, Risks, and Contingencies
The Sublease is subject and subordinate to Roche's lease agreement with the landlord. The agreement includes customary covenants, indemnities, defaults, and security deposits. The full text of the Sublease will be filed as an exhibit to the Company's Annual Report on Form 10-K for the year ending December 31, 2020.
Investor Verification Checklist
- Verify the total square footage (19,112 sq. ft.) and location (80 Guest Street, Brighton, MA) of the new facility.
- Confirm the start date of rent payments (January 1, 2021) and the 2.5% annual escalation clause.
- Review the full Sublease agreement in the upcoming Form 10-K for specific details on operating expense calculations and indemnity provisions.
- Monitor the relocation timeline to ensure the move from Cambridge to Brighton occurs as scheduled in January 2021.